10.1007/s12020-024-03706-6 Endocrine 71 YehP.-K.AnY.-C.HungK.-S.YangF.-C
All data supporting the findings of this study are available within the paper and its Supplementary Information
Clin Epidemiol 16:30718 Rasmussen L, Andersen JH, Karlstad , Giunta DH, Linder M, Furu K et al (2024) Early uptake of semaglutide for type 2 diabetes in Scandinavia and characteristics of initiators in Denmark: a register-based drug utilization study
Sophie Lund-Yates, analista principal de acciones de Hargreaves Lansdown, dijo en el programa Wake Up to Money de la BBC que Novo Nordisk qued "muy sorprendida" ante la gran aceptacin del tratamiento, lo que coloc a la empresa en una posicin de "vctima de su propio xito"
Typically, these symptoms are transient and diminish over time as the patients body adapts to the treatment
In the medication category known as glucagon-like peptide-1 (GLP-1) receptor agonists, semaglutide stimulates the production of insulin for efficient blood glucose regulation and slows down stomach emptying, promoting a longer feeling of fullness